These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21207017)

  • 1. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis.
    Chen P; Wang L; Liu B; Zhang HZ; Liu HC; Zou Z
    Eur J Clin Pharmacol; 2011 Mar; 67(3):235-43. PubMed ID: 21207017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
    Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Pan G; Ke S; Zhao J
    Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
    Yan H; Li Q; Wang W; Zhen H; Cao B
    Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
    Zhu CM; Lian XY; Zhang HY; Bai L; Yun WJ; Zhao RH; Li QS
    J Cancer Res Ther; 2021 Jul; 17(3):664-670. PubMed ID: 34269297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
    Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
    PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis.
    Luo W; Li Y; Ye F; Li Q; Zhang G; Li J; Li X
    Medicine (Baltimore); 2021 Nov; 100(47):e27954. PubMed ID: 34964780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
    Xu R; Shao H; Zhu J; Ju Q; Shi H
    Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
    Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
    Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis.
    Yang Y; Wang L; Li X; Zhang S; Yu J; Nie X; Liu W; Wu X; Zhang P; Li Y; Li A; Ai B
    Thorac Cancer; 2022 Jan; 13(1):31-37. PubMed ID: 34859599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Ibrahim EM; Abouelkhair KM; Al-Masri OA; Chaudry NC; Kazkaz GA
    Lung; 2011 Jun; 189(3):193-8. PubMed ID: 21424607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.
    Zhang JW; Zhao YY; Guo Y; Xue C; Hu ZH; Huang Y; Zhao HY; Zhang J; Wu X; Fang WF; Ma YX; Zhang L
    Chin J Cancer; 2014 Feb; 33(2):105-14. PubMed ID: 23816558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
    Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
    [No Abstract]   [Full Text] [Related]  

  • 19. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.
    OuYang PY; Su Z; Mao YP; Deng W; Xie FY
    PLoS One; 2013; 8(11):e79000. PubMed ID: 24236082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.